Several observations point toward the possibility of a vaccine development strategy against the disease-associated blood stage form of the malaria parasite. Protection against clinical malaria ...

“It’s really important for the children, for their health," she said. In 2021, WHO endorsed the first malaria vaccine, known as Mosquirix, made by GSK. But that vaccine requires four doses and ...

Last week, GlaxoSmithKline said it was investing "at pace" in mRNA vaccines, with more than 200 ... at other candidates for indications like flu, malaria, tuberculosis, rabies and respiratory ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK, known for developing vaccines against infectious diseases like shingles and influenza, has also been actively advancing new vaccines, including the recently approved respiratory syncytial ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

(Reuters) - GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...